For the first time,European Society of Cardiology(EsC)guidelines have aggregated in 1 single document recommendations for the management of patients with non-ST-segment elevation acute coronary syndromes(NSTE-ACS)and ...For the first time,European Society of Cardiology(EsC)guidelines have aggregated in 1 single document recommendations for the management of patients with non-ST-segment elevation acute coronary syndromes(NSTE-ACS)and ST-elevation myocardial infarction(STEMI).From a clinical perspective,this is coherent,as the spectrum of clinical presentations in acute coronary syndromes(ACS)may range from new onset or progressive troponin-negative angina to STEMl,cardiogenic shock,or cardiac arrest.In addition,the management pathways of NSTE-ACS and STEMI patients are widely similar.Compared with previous editions of the guidelines,the extensive document is improved also from a graphic perspective,containing several appealing and easy-to-understand figures.New or modified recommendations include,among others,the topics of diagnostic work-up,timing of invasive strategy,revascularization in multi-vessel disease,intravascular imaging,cardiac arrest,cardiogenic shock,and antithrombotic treatment.For the first time in the field of ACS,ESC guidelines have incorporated a section on patient perspectives with dedicated recommendations.Some of the most relevant changes in recommendations impacting clinical practice are discussed inthis article.展开更多
2018版欧洲心脏病学会/欧洲高血压学会(European Society of Cardiology/European Society of Hypertension,ESC/ESH)高血压指南于8月25日正式发表,新版指南延续了2013版指南严谨沉稳、全面精细的特点,又在多方面进行了更新,尤其是降压...2018版欧洲心脏病学会/欧洲高血压学会(European Society of Cardiology/European Society of Hypertension,ESC/ESH)高血压指南于8月25日正式发表,新版指南延续了2013版指南严谨沉稳、全面精细的特点,又在多方面进行了更新,尤其是降压目标的分层、细化以及起始A+C或A+D的联合治疗方案成为亮点。此外,在风险评估与管理、正常高值高危患者的治疗、高血压合并脑卒中、糖尿病、冠心病、慢性肾脏病、心力衰竭等方面均有更新和补充。本文就新版指南的主要内容和更新进行介绍和解读。展开更多
欧洲心脏病学会(European Society of Cardiology,ESC)2022年发布的室性心律失常与心脏猝死的预防管理指南是对2015年ESC发布的指南的更新,其中有诸多新增内容与更新推荐。指南增加了公共基础生命支持、基因检测、危险评估等推荐,更新...欧洲心脏病学会(European Society of Cardiology,ESC)2022年发布的室性心律失常与心脏猝死的预防管理指南是对2015年ESC发布的指南的更新,其中有诸多新增内容与更新推荐。指南增加了公共基础生命支持、基因检测、危险评估等推荐,更新了室性心律失常的相关治疗推荐,目的是更好地指导临床。展开更多
目前,几乎所有抗肿瘤的药物和非药物治疗方法都可直接造成心脏和血管损伤,且恶性肿瘤与心血管疾病常伴有共同的危险因素,故心血管疾病已成为老年肿瘤患者致死的重要原因,严重恶化患者预后。2022年8月26日,在巴塞罗那举行的欧洲心脏病学...目前,几乎所有抗肿瘤的药物和非药物治疗方法都可直接造成心脏和血管损伤,且恶性肿瘤与心血管疾病常伴有共同的危险因素,故心血管疾病已成为老年肿瘤患者致死的重要原因,严重恶化患者预后。2022年8月26日,在巴塞罗那举行的欧洲心脏病学会(European Society of Cardiology,ESC)年会上,首部肿瘤心脏病学指南隆重发布,该指南由ESC联合欧洲血液病协会(European Hematology Association,EHA)。展开更多
ST elevation myocardial infarction (STEMI) occupies a significant portion of the cardiovascular disease spectrum and poses a continuing challenge on the health care delivery system worldwide. A dilemma exists in the c...ST elevation myocardial infarction (STEMI) occupies a significant portion of the cardiovascular disease spectrum and poses a continuing challenge on the health care delivery system worldwide. A dilemma exists in the clinical triage system for appropriate strategic modalities of treatment, based on underlying triad of patient-hospital-cardiac pathological factors as well as cut off timelines. Current European Society of Cardiology (ESC) guideline recommends percutaneous coronary intervention (PCI) within 3 to 24 hours in post thrombolysis stable patients. This review critically evaluated the evidences underlying the ESC recommendation. Trials included in this review are SIAM III, GRACIA 1, CAPITAL-AMI, CARESS-IN-AMI, NORDISTEMI, PRAGUE-1, WEST and LEIPZIG. Most of the evidences support the notion for immediate post thrombolysis PCI in stable patients within 1.9 to 2.7 hours, which contradicts the ESC timeline of up to 24 hours. Also, there is a reduced generalizability of the trial results due to differences in the design of the various trials, study population, composite endpoints, variations in drug dose & formulation, co-administration of pharmacotherapies and type of stents used. This warrants further research for standardization & optimization of the treatment protocol with respect to post thrombolysis PCI in stable STEMI patients.展开更多
欧洲心脏病学会(European Society of Cardiology,ESC)于2024年8月30日发布了《2024年ESC血压升高和高血压管理指南》。该指南对2018年《动脉高血压管理指南》进行了更新,这一重要更新为引入血压升高的概念(120~139/70~89 mm Hg),并为...欧洲心脏病学会(European Society of Cardiology,ESC)于2024年8月30日发布了《2024年ESC血压升高和高血压管理指南》。该指南对2018年《动脉高血压管理指南》进行了更新,这一重要更新为引入血压升高的概念(120~139/70~89 mm Hg),并为大多数接受降压药物治疗的患者提出120~129 mm Hg的新收缩压治疗目标。此外,该指南在生活干预、高血压器械治疗等方面新增或修订了诸多内容。本文对该指南血压升高及高血压的定义和分类以及心血管疾病风险评估、诊断及病因、预防和治疗三大方面进行解读,并与2018年《动脉高血压管理指南》和2017年《ACC/AHA成人高血压的预防、检测、评估和管理指南》进行对比。展开更多
文摘For the first time,European Society of Cardiology(EsC)guidelines have aggregated in 1 single document recommendations for the management of patients with non-ST-segment elevation acute coronary syndromes(NSTE-ACS)and ST-elevation myocardial infarction(STEMI).From a clinical perspective,this is coherent,as the spectrum of clinical presentations in acute coronary syndromes(ACS)may range from new onset or progressive troponin-negative angina to STEMl,cardiogenic shock,or cardiac arrest.In addition,the management pathways of NSTE-ACS and STEMI patients are widely similar.Compared with previous editions of the guidelines,the extensive document is improved also from a graphic perspective,containing several appealing and easy-to-understand figures.New or modified recommendations include,among others,the topics of diagnostic work-up,timing of invasive strategy,revascularization in multi-vessel disease,intravascular imaging,cardiac arrest,cardiogenic shock,and antithrombotic treatment.For the first time in the field of ACS,ESC guidelines have incorporated a section on patient perspectives with dedicated recommendations.Some of the most relevant changes in recommendations impacting clinical practice are discussed inthis article.
文摘2018版欧洲心脏病学会/欧洲高血压学会(European Society of Cardiology/European Society of Hypertension,ESC/ESH)高血压指南于8月25日正式发表,新版指南延续了2013版指南严谨沉稳、全面精细的特点,又在多方面进行了更新,尤其是降压目标的分层、细化以及起始A+C或A+D的联合治疗方案成为亮点。此外,在风险评估与管理、正常高值高危患者的治疗、高血压合并脑卒中、糖尿病、冠心病、慢性肾脏病、心力衰竭等方面均有更新和补充。本文就新版指南的主要内容和更新进行介绍和解读。
文摘欧洲心脏病学会(European Society of Cardiology,ESC)2022年发布的室性心律失常与心脏猝死的预防管理指南是对2015年ESC发布的指南的更新,其中有诸多新增内容与更新推荐。指南增加了公共基础生命支持、基因检测、危险评估等推荐,更新了室性心律失常的相关治疗推荐,目的是更好地指导临床。
文摘目前,几乎所有抗肿瘤的药物和非药物治疗方法都可直接造成心脏和血管损伤,且恶性肿瘤与心血管疾病常伴有共同的危险因素,故心血管疾病已成为老年肿瘤患者致死的重要原因,严重恶化患者预后。2022年8月26日,在巴塞罗那举行的欧洲心脏病学会(European Society of Cardiology,ESC)年会上,首部肿瘤心脏病学指南隆重发布,该指南由ESC联合欧洲血液病协会(European Hematology Association,EHA)。
文摘ST elevation myocardial infarction (STEMI) occupies a significant portion of the cardiovascular disease spectrum and poses a continuing challenge on the health care delivery system worldwide. A dilemma exists in the clinical triage system for appropriate strategic modalities of treatment, based on underlying triad of patient-hospital-cardiac pathological factors as well as cut off timelines. Current European Society of Cardiology (ESC) guideline recommends percutaneous coronary intervention (PCI) within 3 to 24 hours in post thrombolysis stable patients. This review critically evaluated the evidences underlying the ESC recommendation. Trials included in this review are SIAM III, GRACIA 1, CAPITAL-AMI, CARESS-IN-AMI, NORDISTEMI, PRAGUE-1, WEST and LEIPZIG. Most of the evidences support the notion for immediate post thrombolysis PCI in stable patients within 1.9 to 2.7 hours, which contradicts the ESC timeline of up to 24 hours. Also, there is a reduced generalizability of the trial results due to differences in the design of the various trials, study population, composite endpoints, variations in drug dose & formulation, co-administration of pharmacotherapies and type of stents used. This warrants further research for standardization & optimization of the treatment protocol with respect to post thrombolysis PCI in stable STEMI patients.
文摘欧洲心脏病学会(European Society of Cardiology,ESC)于2024年8月30日发布了《2024年ESC血压升高和高血压管理指南》。该指南对2018年《动脉高血压管理指南》进行了更新,这一重要更新为引入血压升高的概念(120~139/70~89 mm Hg),并为大多数接受降压药物治疗的患者提出120~129 mm Hg的新收缩压治疗目标。此外,该指南在生活干预、高血压器械治疗等方面新增或修订了诸多内容。本文对该指南血压升高及高血压的定义和分类以及心血管疾病风险评估、诊断及病因、预防和治疗三大方面进行解读,并与2018年《动脉高血压管理指南》和2017年《ACC/AHA成人高血压的预防、检测、评估和管理指南》进行对比。
